Myeloproliferative Neoplasms Forecast in 12 Major Markets 2017-2027

DUBLIN, November 3, 2017 /PRNewswire/ --

The "Myeloproliferative Neoplasms Forecast in 12 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Myeloproliferative neoplasms (MPNs) are a group of diseases that concern the clonal proliferation of precursors of the myeloid lineage cells in the bone marrow. MPNs are characterized by uncontrolled cell growth, and therefore can also be classified as a type of blood cancer.

This report provides the current prevalent population for three types of MPNs: polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Brazil) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight, JAK2-V617F mutation status, several clinical and laboratory parameters, as well as some main symptoms and co-morbidities of the covered MPNs and features thereof have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for MPNs include:

• Thrombosis
• Splenomegaly
• Hepatomegaly
• Incident leukaemia
• Anaemia
• Portal hypertension
  

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Comorbid Conditions / Features Associated With the Disease
8. Methodology for Quantification of Patient Numbers
9. Top-Line Prevalence for Myeloproliferative Neoplasms
10. Top Line Prevalence for Polycythaemia Vera
11. Top Line Prevalence for Essential Thrombocythaemia
12. Top Line Prevalence for Primary Myelofibrosis
13. Features of Myeloproliferative Neoplasms Patients
14. Features of Polycythaemia Vera Patients
15. Features of Essential Thrombocythaemia Patients
16. Features of Primary Myelofibrosis Patients
17. Comorbid Conditions of Myeloproliferative Neoplasms Patients
18. Comorbid Conditions of Polycythaemia Vera Patients
19. Comorbid Conditions of Essential Thrombocythaemia Patients
20. Comorbid Conditions of Primary Myelofibrosis Patients
21. Abbreviations Used in the Report
22. Other Publications
23. Online Patient-Based Databases
24. Patient-Based Offering
25. Online Pricing Data & Platforms
26. References
27. Appendix
    

For more information about this report visit https://www.researchandmarkets.com/research/zbkl28/myeloproliferative

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]